Pomerantz LLP Launches Investigation Into Ionis Pharmaceuticals
Ionis Pharmaceuticals shares plummeted 23.9% on July 9, 2026, after the company revealed its late-stage CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua failed to hit its primary endpoint. The stock dropped $20.19 to close at $64.27, triggering a formal inquiry by the law firm Pomerantz LLP.
Pomerantz LLP is currently examining whether Ionis or its executives engaged in securities fraud or other unlawful business practices following the trial failure. The investigation focuses on potential breaches of fiduciary duty and corporate misconduct surrounding the development of the drug, which was created in collaboration with AstraZeneca.
Investors who held positions in Ionis during the relevant period are being urged to contact Danielle Peyton at Pomerantz LLP to discuss their legal rights. The firm, a veteran in securities class action litigation with offices spanning from New York to Tel Aviv, seeks to determine if shareholders were misled regarding the prospects of the Wainua treatment prior to the clinical data release.
Comments (0)
No comments yet. Be the first!